CAR T-cell therapy in multiple myeloma: mission accomplished?
Leo Rasche, Michael Hudecek, Hermann Einsele
Abstract
ABSTRACT: B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells are the most potent treatment against multiple myeloma (MM). Here, we review the increasing body of clinical and correlative preclinical data that support their inclusion into firstline therapy and sequencing before T-cell-engaging antibodies. The ambition to cure MM with (BCMA-)CAR T cells is informed by genomic and phenotypic analysis that assess BCMA expression for patient stratification and monitoring, steadily improving early diagnosis and management of side effects, and advances in rapid, scalable CAR T-cell manufacturing to improve access.
Topics & Concepts
Chimeric antigen receptorCAR T-cell therapyMultiple myelomaMedicineCytokine release syndromeAntigenAntibodyCell therapyT cellImmunologyCancer researchCellComputational biologyBiologyImmune systemGeneticsCAR-T cell therapy researchViral Infectious Diseases and Gene Expression in InsectsMultiple Myeloma Research and Treatments